Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Publisher Correction: Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugs.

Golder MR, Liu J, Andersen JN, Shipitsin MV, Vohidov F, Nguyen HV, Ehrlich DC, Huh SJ, Vangamudi B, Economides KD, Neenan AM, Ackley JC, Baddour J, Paramasivan S, Brady SW, Held EJ, Reiter LA, Saucier-Sawyer JK, Kopesky PW, Chickering DE, Blume-Jensen P, Johnson JA.

Nat Biomed Eng. 2018 Sep;2(9):707. doi: 10.1038/s41551-018-0299-6.

PMID:
31015683
2.

Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugs.

Golder MR, Liu J, Andersen JN, Shipitsin MV, Vohidov F, Nguyen HV, Ehrlich DC, Huh SJ, Vangamudi B, Economides KD, Neenan AM, Ackley JC, Baddour J, Paramasivan S, Brady SW, Held EJ, Reiter LA, Saucier-Sawyer JK, Kopesky PW, Chickering DE, Blume-Jensen P, Johnson JA.

Nat Biomed Eng. 2018 Nov;2(11):822-830. doi: 10.1038/s41551-018-0279-x. Epub 2018 Aug 20. Erratum in: Nat Biomed Eng. 2018 Sep;2(9):707.

3.

Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer.

Blume-Jensen P, Berman DM, Rimm DL, Shipitsin M, Putzi M, Nifong TP, Small C, Choudhury S, Capela T, Coupal L, Ernst C, Hurley A, Kaprelyants A, Chang H, Giladi E, Nardone J, Dunyak J, Loda M, Klein EA, Magi-Galluzzi C, Latour M, Epstein JI, Kantoff P, Saad F.

Clin Cancer Res. 2015 Jun 1;21(11):2591-600. doi: 10.1158/1078-0432.CCR-14-2603. Epub 2015 Mar 2.

4.

Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality.

Shipitsin M, Small C, Giladi E, Siddiqui S, Choudhury S, Hussain S, Huang YE, Chang H, Rimm DL, Berman DM, Nifong TP, Blume-Jensen P.

Proteome Sci. 2014 Jul 12;12:40. doi: 10.1186/1477-5956-12-40. eCollection 2014.

5.

Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error.

Shipitsin M, Small C, Choudhury S, Giladi E, Friedlander S, Nardone J, Hussain S, Hurley AD, Ernst C, Huang YE, Chang H, Nifong TP, Rimm DL, Dunyak J, Loda M, Berman DM, Blume-Jensen P.

Br J Cancer. 2014 Sep 9;111(6):1201-12. doi: 10.1038/bjc.2014.396. Epub 2014 Jul 17.

6.

Identification of direct target engagement biomarkers for kinase-targeted therapeutics.

Paweletz CP, Andersen JN, Pollock R, Nagashima K, Hayashi ML, Yu SU, Guo H, Bobkova EV, Xu Z, Northrup A, Blume-Jensen P, Hendrickson RC, Chi A.

PLoS One. 2011;6(10):e26459. doi: 10.1371/journal.pone.0026459. Epub 2011 Oct 24.

7.

PDK1 attenuation fails to prevent tumor formation in PTEN-deficient transgenic mouse models.

Ellwood-Yen K, Keilhack H, Kunii K, Dolinski B, Connor Y, Hu K, Nagashima K, O'Hare E, Erkul Y, Di Bacco A, Gargano D, Shomer NH, Angagaw M, Leccese E, Andrade P, Hurd M, Shin MK, Vogt TF, Northrup A, Bobkova EV, Kasibhatla S, Bronson RT, Scott ML, Draetta G, Richon V, Kohl N, Blume-Jensen P, Andersen JN, Kraus M.

Cancer Res. 2011 Apr 15;71(8):3052-65. doi: 10.1158/0008-5472.CAN-10-2282.

8.

Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor.

Nagashima K, Shumway SD, Sathyanarayanan S, Chen AH, Dolinski B, Xu Y, Keilhack H, Nguyen T, Wiznerowicz M, Li L, Lutterbach BA, Chi A, Paweletz C, Allison T, Yan Y, Munshi SK, Klippel A, Kraus M, Bobkova EV, Deshmukh S, Xu Z, Mueller U, Szewczak AA, Pan BS, Richon V, Pollock R, Blume-Jensen P, Northrup A, Andersen JN.

J Biol Chem. 2011 Feb 25;286(8):6433-48. doi: 10.1074/jbc.M110.156463. Epub 2010 Nov 30.

9.

Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.

Andersen JN, Sathyanarayanan S, Di Bacco A, Chi A, Zhang T, Chen AH, Dolinski B, Kraus M, Roberts B, Arthur W, Klinghoffer RA, Gargano D, Li L, Feldman I, Lynch B, Rush J, Hendrickson RC, Blume-Jensen P, Paweletz CP.

Sci Transl Med. 2010 Aug 4;2(43):43ra55. doi: 10.1126/scitranslmed.3001065.

10.

Discovery of PDK1 kinase inhibitors with a novel mechanism of action by ultrahigh throughput screening.

Bobkova EV, Weber MJ, Xu Z, Zhang YL, Jung J, Blume-Jensen P, Northrup A, Kunapuli P, Andersen JN, Kariv I.

J Biol Chem. 2010 Jun 11;285(24):18838-46. doi: 10.1074/jbc.M109.089946. Epub 2010 Apr 12.

11.

RNA interference for the identification of disease-associated genes.

Nencioni A, Sandy P, Dillon C, Kissler S, Blume-Jensen P, Van Parijs L.

Curr Opin Mol Ther. 2004 Apr;6(2):136-40. Review. Erratum in: Curr Opin Mol Ther. 2005 Jun;7(3):282.

PMID:
15195924
12.

Kit/stem cell factor receptor-induced phosphatidylinositol 3'-kinase signalling is not required for normal development and function of interstitial cells of Cajal in mouse gastrointestinal tract.

Gibbons SJ, Rich A, Distad MA, Miller SM, Schmalz PF, Szurszewski JH, Sha L, Blume-Jensen P, Farrugia G.

Neurogastroenterol Motil. 2003 Dec;15(6):643-53. Erratum in: Neurogastroenterol Motil. 2004 Oct;16(5):629.

PMID:
14651600
13.
14.

Oncogenic kinase signalling.

Blume-Jensen P, Hunter T.

Nature. 2001 May 17;411(6835):355-65. Review.

PMID:
11357143
15.

Two-dimensional phosphoamino acid analysis.

Blume-Jensen P, Hunter T.

Methods Mol Biol. 2001;124:49-65. No abstract available.

PMID:
11100467
16.

Kit/stem cell factor receptor-induced activation of phosphatidylinositol 3'-kinase is essential for male fertility.

Blume-Jensen P, Jiang G, Hyman R, Lee KF, O'Gorman S, Hunter T.

Nat Genet. 2000 Feb;24(2):157-62.

PMID:
10655061
17.

Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction.

Lennartsson J, Blume-Jensen P, Hermanson M, Pontén E, Carlberg M, Rönnstrand L.

Oncogene. 1999 Sep 30;18(40):5546-53.

18.
19.

Involvement of phosphatidylinositol 3'-kinase in stem-cell-factor-induced phospholipase D activation and arachidonic acid release.

Kozawa O, Blume-Jensen P, Heldin CH, Rönnstrand L.

Eur J Biochem. 1997 Aug 15;248(1):149-55.

20.

Identification of the major phosphorylation sites for protein kinase C in kit/stem cell factor receptor in vitro and in intact cells.

Blume-Jensen P, Wernstedt C, Heldin CH, Rönnstrand L.

J Biol Chem. 1995 Jun 9;270(23):14192-200.

21.

Fibroblast growth factor receptor-1 regulation of Src family kinases.

Landgren E, Blume-Jensen P, Courtneidge SA, Claesson-Welsh L.

Oncogene. 1995 May 18;10(10):2027-35.

PMID:
7761103
22.

Modulation of Kit/stem cell factor receptor-induced signaling by protein kinase C.

Blume-Jensen P, Rönnstrand L, Gout I, Waterfield MD, Heldin CH.

J Biol Chem. 1994 Aug 26;269(34):21793-802.

23.

Increased Kit/SCF receptor induced mitogenicity but abolished cell motility after inhibition of protein kinase C.

Blume-Jensen P, Siegbahn A, Stabel S, Heldin CH, Rönnstrand L.

EMBO J. 1993 Nov;12(11):4199-209.

24.
25.

Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis.

Blume-Jensen P, Claesson-Welsh L, Siegbahn A, Zsebo KM, Westermark B, Heldin CH.

EMBO J. 1991 Dec;10(13):4121-8.

26.

Proopiomelanocortin producing cells of spleen: increase after transplantation with opioid-peptide producing Ehrlich ascites tumor cells.

Larsson LI, Blume-Jensen P, Skovsgaard T, Scopsi L.

Eur J Cell Biol. 1988 Dec;47(2):373-8.

PMID:
3243289

Supplemental Content

Loading ...
Support Center